RT Journal Article
T1 Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
A1 Ritte, Rebecca
A1 Lukanova, Annekatrin
A1 Berrino, Franco
A1 Dossus, Laure
A1 Tjønneland, Anne
A1 Olsen, Anja
A1 Overvad, Thure Filskov
A1 Overvad, Kim
A1 Clavel-Chapelon, Françoise
A1 Fournier, Agnès
A1 Fagherazzi, Guy
A1 Rohrmann, Sabine
A1 Teucher, Birgit
A1 Boeing, Heiner
A1 Aleksandrova, Krasimira
A1 Trichopoulou, Antonia
A1 Lagiou, Pagona
A1 Trichopoulos, Dimitrios
A1 Palli, Domenico
A1 Sieri, Sabina
A1 Panico, Salvatore
A1 Tumino, Rosario
A1 Vineis, Paolo
A1 Quirós, José Ramón
A1 Buckland, Genevieve
A1 Sanchez-Perez, Maria-Jose
A1 Amiano, Pilar
A1 Chirlaque, María-Dolores
A1 Ardanaz, Eva
A1 Sund, Malin
A1 Lenner, Per
A1 Bueno-de-Mesquita, Bas
A1 van Gils, Carla H
A1 Peeters, Petra Hm
A1 Krum-Hansen, Sanda
A1 Gram, Inger Torhild
A1 Lund, Eiliv
A1 Khaw, Kay-Tee
A1 Wareham, Nick
A1 Allen, Naomi E
A1 Key, Timothy J
A1 Romieu, Isabelle
A1 Rinaldi, Sabina
A1 Siddiq, Afshan
A1 Cox, David
A1 Riboli, Elio
A1 Kaaks, Rudolf
K1 Receptores de Progesterona
K1 Receptores Estrogénicos
K1 Factores de Edad
K1 Adiposidad
K1 Neoplasias de la mama
K1 Estudios de cohortes
K1 Estudios Prospectivos
K1 Factores de riesgo
AB INTRODUCTIONAssociations of hormone-receptor positive breast cancer with excess adiposity are reasonably well characterized; however, uncertainty remains regarding the association of body mass index (BMI) with hormone-receptor negative malignancies, and possible interactions by hormone replacement therapy (HRT) use.METHODSWithin the European EPIC cohort, Cox proportional hazards models were used to describe the relationship of BMI, waist and hip circumferences with risk of estrogen-receptor (ER) negative and progesterone-receptor (PR) negative (n = 1,021) and ER+PR+ (n = 3,586) breast tumors within five-year age bands. Among postmenopausal women, the joint effects of BMI and HRT use were analyzed.RESULTSFor risk of ER-PR- tumors, there was no association of BMI across the age bands. However, when analyses were restricted to postmenopausal HRT never users, a positive risk association with BMI (third versus first tertile HR = 1.47 (1.01 to 2.15)) was observed. BMI was inversely associated with ER+PR+ tumors among women aged ≤49 years (per 5 kg/m2 increase, HR = 0.79 (95%CI 0.68 to 0.91)), and positively associated with risk among women ≥65 years (HR = 1.25 (1.16 to 1.34)). Adjusting for BMI, waist and hip circumferences showed no further associations with risks of breast cancer subtypes. Current use of HRT was significantly associated with an increased risk of receptor-negative (HRT current use compared to HRT never use HR: 1.30 (1.05 to 1.62)) and positive tumors (HR: 1.74 (1.56 to 1.95)), although this risk increase was weaker for ER-PR- disease (Phet = 0.035). The association of HRT was significantly stronger in the leaner women (BMI ≤22.5 kg/m2) than for more overweight women (BMI ≥25.9 kg/m2) for, both, ER-PR- (HR: 1.74 (1.15 to 2.63)) and ER+PR+ (HR: 2.33 (1.84 to 2.92)) breast cancer and was not restricted to any particular HRT regime.CONCLUSIONSAn elevated BMI may be positively associated with risk of ER-PR- tumors among postmenopausal women who never used HRT. Furthermore, postmenopausal HRT users were at an increased risk of ER-PR- as well as ER+PR+ tumors, especially among leaner women. For hormone-receptor positive tumors, but not for hormone-receptor negative tumors, our study confirms an inverse association of risk with BMI among young women of premenopausal age. Our data provide evidence for a possible role of sex hormones in the etiology of hormone-receptor negative tumors.
PB BioMed Central
SN 1465-5411
YR 2012
FD 2012-05-14
LK http://hdl.handle.net/10668/1324
UL http://hdl.handle.net/10668/1324
LA en
NO Ritte R, Lukanova A, Berrino F, Dossus L, Tjønneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012; 14(3):R76
NO Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 9, 2025